Accelerated immune response to DNA vaccines

被引:20
作者
Zhang, L
Widera, G
Bleecher, S
Zaharoff, DA
Mossop, B
Rabussay, D
机构
[1] Genetron Inc, San Diego, CA 92121 USA
[2] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA
关键词
D O I
10.1089/104454903322625028
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
DNA vaccines offer considerable promise for improvement over conventional vaccines. For the crucial step of delivering DNA vaccines intracellularly, electroporation (EP) has proven to be highly effective. This method has yielded powerful humoral and cellular responses in various species, including nonhuman primates. In an attempt to further improve DNA vaccination we used micron-size gold particles (which do not bind or adsorb DNA) as a particulate adjuvant which was coinjected with DNA intramuscularly into mice, followed by EP of the target site. The presence of gold particles accelerated the antibody response significantly. Maximum titers against hepatitis B surface antigen (HBsAg) were reached after one boost in 6 weeks, whereas 8 weeks were required without particles. These immunizations were effective in protecting mice against tumor challenge with cancer cells expressing HBsAg as a surrogate cancer antigen. Computer modeling of electric fields and gene expression studies indicate that gold particles do not stimulate EP and subsequent antigen expression. The particles may act as an attractant for immune cells, especially antigen presenting cells. We conclude that particulate adjuvants combined with DNA vaccine delivery by EP reduces the immune response time and may increase vaccine efficacy. This method may become valuable for developing prophylactic as well as therapeutic vaccines. The rapid response may be of particular interest in countering bio-terrorism.
引用
收藏
页码:815 / 822
页数:8
相关论文
共 34 条
[1]   Current status of DNA vaccines and their route of administration [J].
Alpar, HO ;
Bramwell, VW .
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2002, 19 (4-5) :307-383
[2]   Electroporation improves the efficacy of DNA vaccines in large animals [J].
Babiuk, S ;
Baca-Estrada, ME ;
Foldvari, M ;
Storms, M ;
Rabussay, D ;
Widera, G ;
Babiuk, LA .
VACCINE, 2002, 20 (27-28) :3399-3408
[3]  
BRATTAIN MG, 1980, CANCER RES, V40, P2142
[4]   Medical applications of electroporation [J].
Dev, SB ;
Rabussay, DP ;
Widera, G ;
Hofmann, GA .
IEEE TRANSACTIONS ON PLASMA SCIENCE, 2000, 28 (01) :206-223
[5]   Technical and regulatory hurdles for DNA vaccines [J].
Donnelly, J ;
Berry, K ;
Ulmer, JB .
INTERNATIONAL JOURNAL FOR PARASITOLOGY, 2003, 33 (5-6) :457-467
[6]   Antigen presentation and DNA vaccines [J].
Donnelly, JJ ;
Liu, MA ;
Ulmer, JB .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 162 (04) :S190-+
[7]   Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice [J].
Dupuis, M ;
Denis-Mize, K ;
Woo, C ;
Goldbeck, C ;
Selby, MJ ;
Chen, MC ;
Otten, GR ;
Ulmer, JB ;
Donnelly, JJ ;
Ott, G ;
McDonald, DM .
JOURNAL OF IMMUNOLOGY, 2000, 165 (05) :2850-2858
[8]   Effect of Electrically Mediated Intratumor and Intramuscular Delivery of a Plasmid Encoding IFN α on Visible B16 Mouse Melanomas [J].
Heller, Loree C. ;
Ingram, Stephanie F. ;
Lucas, M. Lee ;
Gilbert, Richard A. ;
Heller, Richard .
TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2002, 1 (03) :205-209
[9]  
HELLER R, 2003, PRECLINICA, V1, P198
[10]   Protection against influenza virus infection in mice immunized administration of hemagglutinin-expressing DNAs with electroporation [J].
Kadowaki, S ;
Chen, Z ;
Asanuma, H ;
Aizawa, C ;
Kurata, T ;
Tamura, S .
VACCINE, 2000, 18 (25) :2779-2788